Epidemiology of hidradenitis suppurativa and its comorbid conditions - 01/12/24
Abstract |
Hidradenitis suppurativa (HS) is a chronic, inflammatory condition predominantly affecting younger adults and disproportionately affecting women and Black Americans. Estimated prevalences vary significantly according to study methodology; however, true prevalence may range from approximately 0.1% to 1%. Hidradenitis suppurativa is associated with a number of comorbid conditions which also contribute to poor health outcomes and negative impact on quality of life. Recent advancements in our understanding of disease burden in hidradenitis suppurativa have allowed us to identify subgroups of the population afflicted with the disease and to implement strategies which facilitate comprehensive care.
Le texte complet de cet article est disponible en PDF.Key words : comorbidities, epidemiology, guidelines, hidradenitis suppurativa, prevalence, screening
Abbreviation used : HS
Plan
Funding sources: None. |
|
Patient consent: Not applicable. |
|
Author Disclosures: Dr Garg is an advisor for AbbVie, Aclaris Therapeutics, Anaptys Bio, Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Insmed, Janssen, Novartis, Pfizer, Sonoma Biotherapeutics, UCB, Union Therapeutics, Ventyx Biosciences, and Viela Biosciences; receives honoraria; and receives research grants from AbbVie, UCB, National Psoriasis Foundation, and CHORD COUSIN Collaboration (C3). He is co-copyright holder of the HS-IGA and HiSQOL instruments. Author Midgette has no conflicts of interest to declare. |
|
Reviewer Disclosures: None. |
|
IRB approval status: Not applicable. |
|
Date of release: December 2024. |
|
Expiration date: December 2027. |
Vol 91 - N° 6S
P. S3-S7 - décembre 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?